

# Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?"

Arjen van der Schaaf

Potential competing interests: No potential competing interests to declare.

The authors elaborate on an important issue that may cause confusion and overly optimistic interpretation of trial results. They illustrate their point with clear examples. However, no new scientific insights are presented.